CURRICULUM VITAE
The University of Texas at AustinDivision of Pharmacology and ToxicologyCollege of PharmacyAustin, Texas 78712
www.utexas.edu/pharmacy/divisions/pharmtox/faculty/kehrer.html
10435 Jennys Jump DrAustin, Texas 78733-3216
Paul L. Kehrer, July 21, 1982Marc D. Kehrer, February 27, 1986
Education Watertown Senior High School, Watertown, WI 53094
Purdue University, West Lafayette, IN 47907
Univ. of Iowa College of Medicine, Iowa City, IA 52242
Postdoctoral - Biology Division, Oak Ridge National
Membership - Societies American Association for the Advancement of Science (1975-present) American Association for Cancer Research (1999-present) American Society for Pharmacology and Experimental Therapeutics (1984-present). Chairman,
Society of Toxicology (1982-present); President of Mechanisms Specialty Section, 1998-99Society for Free Radical Biology and Medicine (1988-present; formerly the Oxygen Society)International Society for Free Radical Research (1986-present)Gulf Coast Chapter Society of Toxicology (1989-present) Vice-President 1989; President 1990International Society for the Study of Xenobiotics (ISSX) (1993-97)Western Pharmacology Society (1984-1998)
Awards and Honors 1. Merck Award in Pharmacology (1974 - Purdue) 2. Rho Chi National Pharmacy Honorary 3. Phi Kappa Phi Honorary Society 4. University of Iowa Graduate College Fellowship in Pharmacology 1974-1975 5. Postdoctoral Investigatorship - University of Tennessee-Oak Ridge Graduate School of Biomedical Sciences, Oak Ridge National Laboratory, Biology Division. 1978-1980. 6. University of Texas Summer Research Award - 1981 7. Research Career Development Award - National Institutes of Health (NHLBI) 1984-1989 8. Gustavus Pfeiffer Centennial Endowed Fellowship in Pharmacology - 1985-1991 9. Achievement Award - Society of Toxicology 1989. 10. Gustavus and Louise Pfeiffer Professorship in Toxicology - 1991-present. 11. Zeneca Traveling Lectureship Award, Society of Toxicology 1996.
12. Univ. of Texas College of Pharmacy Alumni Association “Best Friend” Award, Nov. 1, 200113. Distinguished Alumnus Award, Purdue Univ. School of Pharmacy, 2004
Curriculum Vitae Kehrer, J.P. Page 2 Experience Director, Center for Molecular and Cellular Toxicology
Member, US-EPA Science Advisory Board Environmental Health Committee 2003-2006Adjunct Professor, Dept. Carcinogenesis, M.D. Anderson Cancer Center,
Science Park Research DivisionHead, Division of Pharmacology and Toxicology, College of Pharmacy
Professor of Pharmacology - University of Texas at Austin
Guest Scientist - Universität Düsseldorf
Visiting Professor - Institut Für Physiologische Chemie I, Universität Düsseldorf, Düsseldorf, West Germany (with Dr. Helmut Sies)
Associate Professor of Pharmacology - University of Texas at Austin
Assistant Professor of Pharmacology - University of Texas at Austin
Postdoctoral Investigator-Biology Div., Oak Ridge National Laboratory (with Dr. Hanspeter Witschi)
NIH Predoctoral Fellow, Univ. of Iowa (with Dr. Anne P. Autor)
RESEARCH Research Interests •Molecular mechanisms by which acrolein, a cyclophosphamide metabolite, affects apoptosis and cell proliferation; effects on NF-κB; role of acrolein in the anticancer efficacy of this drug
•Thioredoxin and apoptosis; role of thioredoxin in signaling•Mechanisms of apoptosis induced by lipoxygenase and cyclooxygenase-2 inhibitors; role oflipocalin expression (24p3 and NGAL) and Akt signaling pathways•Free radical toxicity; glutathione and apoptosis
Research Support (direct costs) A. Past Funding 1.
Univ. of Texas Research Institute. "Effect of Butylated Hydroxytoluene on PulmonaryGlutathione Levels". $4,800: October 1980-March 31, 1981, Principal Investigator.
Univ. of Texas Research Institute. "The Effect of Corticosteroids on Acutely DamagedPulmonary Tissue," $4,000, Summer Research Award, June 1, 1981-August 31, 1981.
College of Pharmacy BRSG Seed Grant. "Hydroxyproline as an Index of Collagen ContentAfter Acute Lung Damage", $5,000: June 15, 1981-March 31, 1982, Principal Investigator
Univ. of Texas Research Institute. "The Effect of Acute Lung Damage on the Breakdown ofCollagen" $5,000: Sept. 30, 1981-July 31, 1982, Principal Investigator
Gustavus and Louise Pfeiffer Research Foundation. "The Effect of Drug Treatment onDamaged Lung Tissue" $50,023: October 1982-September 1985, Principal Investigator.
College of Pharmacy BRSG Seed Grant. "The Effects of BCNU (carmustine) on PulmonaryGlutathione Reductase". $2,000: June 15, 1982-March 31, 1983, Principal Investigator.
Univ. of Texas Research Institute."The Effect of Drug Treatment on Damaged Lung Tissue". $5,000: October 1982-March 1983, Principal Investigator.
National Institutes of Health (NHLBI). "Effect of Toxic Lung Damage and Steroids onCollagen" $167,612: April 1, 1983-March 31, 1986, Principal Investigator.
American Heart Assoc.-Texas Affiliate. "Enhanced Doxorubicin Cardiotoxicity by BCNU". $28,771: July 1, 1983-June 30, 1984, Principal Investigator.
10. American Cancer Society."Toxic Effects of BCNU: Role of Glutathione Reductase Inhibition."
$72,355: July 1, 1983 - June 30, 1985, Principal Investigator.
11. College of Pharmacy BRSG Seed Grant. "Role of Lipid Peroxide Damage in Chicken
Muscular Dystrophy". $2,000: June 1, 1985 - March 31, 1986.
12. American Cancer Society. "Toxic Interactions of Anticancer Drugs on the Lung"
$37,575: July 1, 1985 - June 30, 1986, Principal Investigator.
13. General Motors Research Institute. "Analysis of Lung Collagen in Ozone-Exposed Rats.
$14,805: Dec. 1985 - Aug. 1986, Principal Investigator
Curriculum Vitae Kehrer, J.P. Page 3
14. University of Texas Research Institute. "Reoxygenation Injury in Isolated Perfused Heart".
$4,500: Oct. 1, 1986 - March 31, 1987, Principal Investigator
15. General Motors Research Institute. "Oxidant Exposure and Pulmonary Fibrosis". $10,274:
Oct. 1987 - Aug. 1988, Principal Investigator
16. National Institutes of Health (NHLBI). "Toxic Lung Damage and the Effect of Steroid
Treatment" Research Career Development Award $237,500: Sept. 1, 1984 - Aug. 31, 1989.
17. Burroughs Wellcome Fund. Wellcome Visiting Professorship for Dr. Helmut Sies, $2500
January, 1990, initiator for this award.
18. General Motors Research Institute. "Oxidant Exposure and Pulmonary Fibrosis". $13,699:
Jan. 1989 - Dec. 1989, Principal Investigator
19. University of Düsseldorf. "Mitochondrial function under defined conditions of hypoxia".
6000DM: May 9, 1990 - June 30, 1990, Principal Investigator
20. Marnac Corporation. "Antifibrotic activity of pirfenidone" $2,000, May 1, 1990 - Aug. 31,
21. College of Pharmacy BRSG Grant. "Chloroethyl 3H labeled cyclophosphamide" $2000, Jan.
22. Marnac Corporation. "Antifibrotic activity of pirfenidone" $2,100, Dec. 1, 1990 - April 30,
23. Clinitec Nutrition. "Effect of glutathione esters on hypoxic heart injury" $5,000: Aug. 1, 1991-
24. National Institutes of Health (NHLBI). "Toxicity of cardiac hypoxia and reoxygenation".
$131,882: Dec. 1, 1988 - Nov. 30, 1991, Principal Investigator
25. American Cancer Society. "Activation of cyclophosphamide via cooxidation" $124,220: July 1,
1992-June 30, 1994, Principal Investigator (duplicate award to NIH so funds not provided)
26. Dermigen Corp. "Effect of antioxidants on hepatotoxicity of endrin and dieldrin" $6,249:
February 1, 1992 - August 31, 1992, Principal Investigator
27. Dermigen Corp. "Effect of antioxidants on hepatotoxicity of endrin and dieldrin" $11,019:
September 1, 1992 - December 31, 1992, Principal Investigator
28. Gustavus and Louise Pfeiffer Research Foundation. "Prevention of lung injury induced by the
anticancer drug cyclophosphamide" $30,000: Feb. 1991-Feb. 1993, Principal Investigator.
29. National Institutes of Health (NHLBI). "Lung Toxic Interactions Involving Therapeutic
Drugs". $351,425: April 1, 1987 - March 31, 1993, Principal Investigator
30. Pharmaceutical Manufacturers Association. Postdoctoral award to Sarath Kanekal "Peroxidase-
mediated metabolism of cyclophosphamide". $31,175: July 1, 1992 - June 30, 1993.
31. HealthQuest "General support" $6,000: January - December, 1993; Principal Investigator32. RJR. "Oxidative stress, thiol redox status and cellular senescence". $22,500: Jan. 1, 1997-Dec.
33. NIEHS Center Grant Pilot Project. "Mechanisms of apoptosis: lipoxygenase enzymes and bcl
protooncogenes". $13,500: July 1, 1997 – June 30, 1998, Principal Investigator
34. NIEHS Center Grant Pilot Project. "Effect of acrolein on gene expression". $15,000: July 1,
1999 – June 30, 2000, Principal Investigator
35. National Institutes of Health (NHLBI). "Cellular reducing equivalents and oxidative stress".
$653,993: August 1, 1994 - July 31, 2000, Principal Investigator
36. National Institutes of Health (NHLBI). "Mechanisms of cyclophosphamide toxicity".
$399,234: Dec. 1, 1995 - Nov. 30, 2000, Principal Investigator
37. National Institutes of Health (NIEHS). "Mechanisms of acrolein on proliferation and
apoptosis". $558,017: Aug. 1, 1999 - July 31, 2003, Principal Investigator
B. Current Funding 1.
National Institutes of Health (NCI). "Apoptosis, 5-lipoxygenase activating protein, and bcl-x ".
$900,000: June 1, 2000 - May 31, 2005, Principal Investigator
NIEHS. "Mechanisms and prevention of environmental disease". Center Grant$3,000,000: April 1, 1996 - March 31, 2001, Director Research Core 1 1996; AssociateDirector, Austin, 1997-present
NIEHS. “Mechanisms of organ-specific toxicology of xenobiotics. Training Grant$320,000; annual costs 7/1/2000-6/30/2003, Training faculty
Curriculum Vitae Kehrer, J.P. Page 4 Journal Editorial Appointments Editor for the Americas and Japan - Toxicology Letters (1993-present) Associate Editor for Reviews - Toxicology Letters (1988-93) Associate Editor - Journal of Toxicology and Environmental Health (1992-93) Deputy Chairman of the Editorial Board - Biochemical Journal (2000-present) Toxicology (1982-1993)Toxicology and Applied Pharmacology (1989-present)Biochemical Journal [editorial advisory panel] (1991-1993)Biochemical Journal (1993-2000)Archives of Biochemistry and Biophysics (2003-present)
National and International Invited Research Lectures and Symposium Participation 1.
"Butylated Hydroxytoluene Induced Pulmonary Toxicity" Dept. of Pharmacology andToxicology, Purdue University, West Lafayette, IN, Nov. 1979
"Butylated Hydroxytoluene Lung Toxicity and the Development of Pulmonary Fibrosis" Dept. of Pharmacology, Southern Illinois Univ. School of Medicine, Springfield, IL, Jan. 1980
"Collagen Metabolism During the Development of Pulmonary Fibrosis"Los Alamos Scientific Laboratory, Los Alamos, NM, Nov. 1980
"Research Frontiers in Pharmacology" Texas Junior Science, Engineering, and HumanitiesSymposium, Joe C. Thompson Conference Center, Austin, TX, Feb. 1981
"Mediators of Lung Toxicity: Activated Metabolites and Oxygen Radicals" Symposium onCellular Mechanisms of Toxicity, Fifth Annual Meeting of Texas Pharmacologists, Lubbock,TX, May, 1981
"The Effect of Butylated Hydroxytoluene on Pulmonary Collagen" Department ofPharmacology, The University of Iowa, Iowa City, IA, October, 1981
"Collagen Synthesis After Acute Lung Damage" College of Pharmacy, University ofWisconsin, Madison, WI, May, 1982
"Paraquat Induced Lung Damage" Abbott Laboratories, North Chicago, IL, August, 1982
"Effects of Corticosteroids on Collagen in Damaged Lung" The Univ. of Texas SystemCancer Center, Smithville, TX, February, 1983
10. "A Comparison of Ranitidine and Cimetidine" Capital Area Pharmacists Association, Austin,
11. "Effects of Corticosteroids on Acutely Damaged Lung" Dept. of Radiation Biology and
Biophysics, University of Rochester Medical Center, Rochester, NY, January, 1984
12. "What's New In Therapeutic Drugs" UT Ex-Students Association - Update 84, Austin, TX,
13. "Measuring Collagen Metabolism in Normal and Damaged Lung Tissue"
Biomedical Sciences Dept., General Motors Research Labs, Warren, MI, October, 1984
14. "New Developments in Therapeutic Drugs" Texas Society of Professional Engineers, Austin,
15. "Drug-Induced Lung Damage: Models and Mechanisms" Institut für Physiologische Chemie
I, Universität Düsseldorf, Düsseldorf, West Germany, February, 1986.
16. "Reactive Oxygen Species in Biological Systems"
Institut Für Anorganische Chemie, Universität Basel, Basel, Switzerland, June, 1986.
17. "Reactive Oxygen in Biological Systems"
Martin Luther Universität, Sektion Pharmazie, Halle, East Germany, June, 1986.
18. "Models and Mechanisms of Drug-Induced Lung Damage" Universität Göttingen, Institut für
Pharmakologie und Toxikologie, Göttingen, West Germany, July, 1986.
19. "Absence of Changes in Xanthine Oxidase During Hypoxia and Reoxygenation of Isolated
Rat Heart". Discussion meeting on "The Role of Oxygen Radicals in CardiovascularDiseases", Asolo, Italy, December, 1986. Curriculum Vitae Kehrer, J.P. Page 5
20. "The Oxygen Paradox: A German Experience". Institut Für Physiologische Chemie I,
Universität Düsseldorf, Düsseldorf, West Germany, December, 1986.
21. Invited discussant to the workshop on "Antioxidant Interactions", part of the workshop on
"Oxygen Radicals and Antioxidants in Cancer and Aging". Univ. California, Berkeley,February, 1987.
22. "Antioxidants in Muscular Dystrophy" Invited speaker, Gordon Research Conference on
"Oxy Radicals in Biology and Medicine", Santa Barbara, CA, February, 1987.
23. "Reoxygenation Injury: Energy or Radicals?" Department of Kinesiology, The University of
24. "Overview of The Role of Free Radicals in Pathogenesis" Chairman of the symposium by the
same name at the 1988 annual Meeting of the Society of Toxicology, Dallas, TX, Feb. 1988.
25. "Is Oxidative Stress a Factor in Muscular Dystrophy or Cardiac Reperfusion Injury?" Dept. of
Pharmacology, College of Pharmacy, The Univ. of Arizona, Tucson, AZ, March 1988.
26. "Energy-Dependence of Enzyme Release From Hypoxic Isolated-Perfused Rat Heart Tissue."
Department of Biochemistry, University of Osaka Medical School, Osaka, Japan. April 1988.
27. "Cardiac Reperfusion Injury: Oxidative Changes and Protection by Ruthenium Red." Johnson
& Johnson, New Brunswick, NJ, May 1989.
28. "Oxidative Stress in Hypoxic Heart Tissue" Dept. of Physiology & Pharmacology, Texas
A & M University Veterinary School, College Station, TX, October 1989.
29. "Hypoxic Heart Injury: Oxidative Stress and Protection by Ruthenium Red" Section of
Cardiovascular Sciences, Baylor College of Medicine, Houston, TX December 1989.
30. "Chemical-Induced Lung Injury and Fibrosis" Univ. of British Columbia, School of
Medicine, Vancouver, BC, Canada, February 1990.
31. "Mechanisms of Hypoxic Cell Injury: Introduction and Overview" Chairman of the
symposium by the same name at the 1990 annual Meeting of the Society of Toxicology,Miami, FL, February 1990.
32. "Free Radicals In Muscular Dystrophy" invited speaker for a symposium on "Chemical
Stimulation of Free Radical Mechanisms of Tissue Injury, American Chemical Societymeeting, Boston, MA April 1990.
33. "Oxidative Stress During Cardiac Hypoxia" Institut of Physiological Chemistry I, University
of Düsseldorf, Federal Republic of Germany, May 1990.
34. "Cooxidation as the Mechanism of Cyclophosphamide-Induced Lung Injury" Institute of
Toxicology, University of Würzburg, Federal Republic of Germany, May 1990.
35. "Cooxidation as a Mechanism of Cyclophosphamide Bioactivation" Department of
Pharmacology, College of Medicine, Texas A & M University, February 1991.
36. "The Mechanism of Cyclophosphamide-Induced Lung Injury: Cooxidation versus P450"
Dept. Pharmacology & Toxicology, College of Medicine, West Virginia University, March1991.
37. "Cooxidation and Hypoxia: Pathways Leading to Reactive Species and Tissue Injury" Dept. of
Pharmacology /Toxicology, College of Pharmacy, Northeast Lousiana Univ., April 1991.
38. "Oxidative Stress During Hypoxia: Excess Radicals or Compromised Defenses", Symposium
on Free Radicals and Oxidative Stress, Gulf Coast Society of Toxicology meeting, SciencePark, TX October 1991.
39. "Cooxidation of Cyclophosphamide: Does it Lead to Lung and Bladder Toxicity?" University
of California, Davis, February 1992.
40. "Redox balance of the hypoxic heart" Univ. Oklahoma, College of Pharmacy, May, 1992. 41. "Effects of oxygen deprivation on cardiac redox systems" Symposium on Molecular
Mechanisms of Ischemia/Reperfusion Injury, Western Pharmacology Society, Incline Village,NV, Feb. 1993
42. "Oxidant toxicity in hypoxic heart tissue", Dept. of Biological Sciences, Southern Methodist
43. "The science of toxicology", LBJ High School Science, Mathematics and Technology
Curriculum Vitae Kehrer, J.P. Page 6
44. "Oxidative stress and the supply of cellular reducing equivalents", Penn State's Thirteenth
Summer Symposium in Molecular Biology" Molecular and Cellular Mechanisms of Toxicity. University Park, PA, August 1994.
45. "Reducing mitochondrial oxidative stress", Dept. of Pharmacology and Toxicology, Indiana
University School of Medicine, Indianapolis, IN, January 1995.
46. "Reducing mitochondrial oxidative stress", Dept. of Pharmacology and Toxicology, School of
Pharmacy, Purdue University, W. Lafayette, IN, January 1995.
47. "Bcl-2 and free radicals, and reducing mitochondrial oxidative stress" Dept. of Pathology,
University of Texas Medical Branch, Galveston, TX, August, 1995.
48. "Oxidative stress: Mitochondrial responses and the role of bcl-2" Dept. of Pharmaceutical
Chemistry, Wayne State University, Detroit, MI, August, 1995.
49. "NIH Grant Writing", Northeast Louisiana University, October 1995. 50. "Oxidative stress, reducing equivalents and bcl-2" Zeneca Pharmaceuticals, Macclesfield,
51. "Oxidative stress, reducing equivalents and bcl-2" MRC Toxicology Unit, Leicester, England,
52. "Oxidative stress, reducing equivalents and bcl-2" Univ. Düsseldorf, Germany, June 199653. "Oxidative stress, reducing equivalents and bcl-2" Leiden University, Center for Drug
Research, Division of Molecular Pharmacology, Amsterdam, The Netherlands, June 1996
54. "Acrolein mercapturates: A factor in cyclophosphamide toxicity?" University of Würzburg,
55. "Oxidants, antioxidants and the Bcl protooncogenes" University of Düsseldorf, Germany, May
56. "Oxidants, antioxidants and the Bcl protooncogenes" University of Konstanz, Germany, June
57. "Oxidants, antioxidants and the Bcl protooncogenes" University of Zurich, Switzerland, June
58. "Lipoxygenase and bcl-xL in apoptotic cell death" University of Houston, December 1997.
59. "5-Lipoxygenase activator protein and bcl-xL in apoptotic cell death" Essen University,
60. "5-Lipoxygenase activating protein (FLAP), bcl-xL and apoptosis" Washington State
61. "5-Lipoxygenase activating protein (FLAP), bcl-xL and apoptosis" Penn State University,
62. "Overview of current research: FLAP and Apoptosis; Acrolein and NF-κB, Proteasome and
hsp70" Oklahoma State University, December 1998.
“Detoxification” Plenary lecture at the NIH workshop on Cellular Responses to Low Dosesof Ionizing radiation, Bethesda, MD April 1999.
"The cause-effect of oxidative stress and apoptosis". Symposium presentation at the annualmeeting of the Teratology Society. Keystone, CO, July 1999.
65. "Basic concepts of toxicology" American Chemical Society Short Course; Washington DC,
Sept. 1999; New Orleans, November 1999; San Francisco, April 2000; Boston, August 2000,Washington DC, August 2000
66. “The Haber-Weiss reaction and mechanisms of toxicity” Workshop presentation at the
annual meeting of the Society of Toxicology. Philadelphia, PA, March 2000
67. “Energy malmetabolism, oxidative stress and toxicological consequences in the heart”
Continuing education presentation at the annual meeting of the Society of Toxicology. Philadelphia, PA, March 2000
68. "Unexpected pathways for xenobiotic-induced apoptosis; focus on lipoxygenase inhibitors"
Texas A&M University, September 2000.
69. “Death becomes her: Pathways to apoptosis”, presentation to Women in Science, Austin, TX
70. “Acrolein and apoptosis; NF-κB, AP-1 and caspases”, Distinguished Speaker in
Environmental Cardiology, University of Louisville, KY, August 2001. Curriculum Vitae Kehrer, J.P. Page 7
71. “Introduction to thioredoxins and thioredoxin reductases: central roles in toxicity and cancer”,
symposium chaired at 2002 annual meeting of the Society of Toxicology
72. Chairman, Session 1, Symposium on “Oxidative stress: health benefits of micronutrients”,
L’Abbaye de Royaumont, Paris, France, July 2002.
73. "Lipocalins, PPARs and apoptosis", Marshall University, Huntington, West Virginia, April
74. "Acrolein, transcription factors and thioredoxin", Wake Forest University, November 2003. 75. "Lipocalins and apoptosis", Symposium presentation at the annual Society of Toxicology
76. "NSAIDs, Peroxisome Proliferators and apoptosis: any role for oxidants?" North Carolina
77. "The Balance Between Life and Death Signaling", Purdue University, November 2004. Curriculum Vitae Kehrer, J.P. Page 8 TEACHING Students Postdoctoral Fellows:
National Science Foundation and Howard Hughes Summer Students
NIH Minority High School Student Research Apprentice Program: Erika Kappe, 1992; Felecia
Special Topics Graduate Students: Special Topics Undergraduate Students: Other Students
Fariba Moraghebi, 2001; M.S. graduate student from Sweden
Graduate Students Supervised:
Thomas Paraidathathu, 1982-84 (M.S. June 1984); 1989-93 (Ph.D. August 1993)Michael E. Murphy, 1985-88 (Ph.D. May, 1988)Younja Park, 1985-1989 (M.S., May 1987; Ph.D. December 1989)Robin Smith, 1984-90 (Ph.D., August 1990)Jairam Palamanda, 1988-92 (Ph.D., August 1992)Lucy Fraiser, 1989-92 (Ph.D., December 1992)Whayoung Lee, 1990-1993 (co-supervisor) Ph.D., December 1993Camarie S. Perry, 1992-1995 (M.S. May 1995)Hanlin Liu, 1992-1995 (M.S. May 1995)Xiang Feng, 1996-1998 (M.S., August 1998)John Robertson, 1995-1999 (Ph.D., May 1999)Julie Kern, 1998-2002 (Ph.D., December 2002)Jonathan Pabalan, 1999-2000 (M.S. December 2000)George Acquaah-Mensah, 1998-2001 (Ph.D., August 2001)Vaidehee Deshpande, 2000-presentElisa Atarod, 2001-2003 (M.S., December 2003)Young Eun Choi, 2001-present
Curriculum Vitae Kehrer, J.P. Page 9
Shreya Metra, 2002-presentDmitriy Ovcharenko, 2004-present
Masters Thesis Committees
Sedelia Lopez; Physical & Health Education, M.S. May 1983 (no thesis)Jon Swift; Kinesiology, M.S. May, 1996Hae-Seong Yoon, M.S., August 1999
Ph.D. Dissertation Committees
Kenneth S. Santone; Pharmacology - Ph.D. 1984Lee James Carmack; Biomedical Engineering - Ph.D. 1987Glen Kisby; Pharmacology - Ph.D. 1986Donald R. Needham-VanDevanter; Medicinal Chemistry - Ph.D. 1986John Swann; Pharmacology - Ph.D. 1989Tina Machu; Pharmacology - Ph.D. 1990Robert W. Reed; Biochemistry - Ph.D. 1990Barbara Hill; Pharmacology - Ph.D. 1991A.D. Gurusinghe - Ph.D. 1989; Monash Univ., Clayton, Melbourne, AustraliaRiq Chacon; Pharmacology - Ph.D. 1991Douglas W. Bowles; Kinesiology - Ph.D. 1992Roberta Grant; Pharmacology - Ph.D. 1994Steven Seiler; Kinesiology - Ph.D. 1995Shujia Pan; Pharmacology - Ph.D., 1994Richard Timothy Miller; Pharmacology - Ph.D., 1996Heather Kliner; Pharmacology - Ph.D., 1996Brennan Harris; Kinesiology - Ph.D. 1999Kelly Towndrow; Pharmacology – Ph.D., 2000Qihong Huang; Pharmacology - Ph.D., 2000Xiang Jing; Nutrition - Ph.D., 2001John Giammona; Pharmacology – Ph.D. 2002John Kern: Medicinal Chemistry – Ph.D. 2002Lora Watts; Pharmacology San Antonio – Ph.D. 2004Ryan Taylor, Kinesiology, Ph.D. 2004Bobby Bhatia; MD Anderson, Science Park – Ph.D. activeYamini Chandrasekaran; Pharmacology – Ph.D. active
Courses Taught Iowa 1977 - Pharmacology 71:120 (Drugs; Their Nature Action and Use) course coordinator. Texas Undergraduate 1980-1984 and
PHR 373N (Pharmacology III) course coordinator alternate semesters;
responsible for 50% of the course each semester including summers.
PHR 173L (Pharmacology Laboratory) 13% of the course 3 times yearly.
PHR 362L (Toxicology of Modern Drugs): 20% of the course each semester.
PHR 362M (experimental toxicology): 20% of the course each Fall.
PHR 348 (New drugs & New drug developments) 100% of the course
PHR 473M (Pharmacology II) 25% of course each semester.
Pharmacotherapeutics IIb; 15% of course each year. Curriculum Vitae Kehrer, J.P. Page 10
GraduateSeminar in Pharmacology: each long semesterToxicological Methods: 15% of the course in Fall or SpringAdvanced Toxicology): 20% of course each year through 1990. Biochemical & Molecular Toxicology: 20% of the course each Spring. Biomedical Pharmacology: 25% of course each Fall, 1998-present
Teaching Honors
Nominated for Pharmacy teaching excellence award, Texas, 1981.
1. Consultant to the Legislative Task Force on Cancer in Texas, 1984. 2. Director, Travis County Water District #18, 2002-present
Research Evaluation Committee for the Texas Junior Science, Engineering, and Humanities Symposium: 1982-1983
University Research Institute grant review committee: 1987-1990.
Research Safety Advisory Committee: 1991 - 1997.
1. Admissions: 1980-1982; 1988-19902. Continuing Education: 1980-19843. Graduate Studies Committee: 1980-present4. Recruitment Subcommittee; Graduate Studies Committee: 1980-83 (Chairman 1980-82)5. Advisory Subcommittee on Equipment Purchases: 19816. Advisory Subcommittee on Teaching Assistantships: 19827. Baccalaureate Curriculum Committee for the Accreditation Review: 19828. Curriculum Committee: 1982 - 19849. Administrative subcommittee of the Graduate Studies Committee: 1984-198910. Financial aid committee: 1985-present; chairman 1988-present11. Departmental Review Committee on Human Research: 1986-198812. Equipment Committee: 1986-1988 (chairman)13. Financial Resources Subcommittee of the Accreditation Review Committee: chairman,198914. Faculty Development Committee: 1990-199315. Pharm.D. Degree Structure Steering Committee: 1990-1991. 16. Space Committee: 1990-1994 , 1999-2000 (chairman)17. All College Seminar Committee: 1994-199618. Graduate Financial Aid Committee: 2000-200219. Library Services Committee, 2000-2002. 20. Executive Committee (promotion and tenure); 1990-present; chair 2002-200321. PharmD/PhD task force (chairman) 2001. 22. Accreditation Self-Study: financial resources (chairman), Steering Committee (member),
College Missions and Goals (member) 2002-2003.
23. Task Force on Pharmacy Enrollment (chairman) 2004
1. Public Relations Committee - Mechanisms Section Society of Toxicology: 1983 - 19842. Chairman, General Toxicology session, Society of Toxicology, 24th Annual Meeting, 1985. 3. Member, Committee on Public Communications, Society of Toxicology, 1985 - 19884. Chairman, Symposium on "Free Radical Mechanisms in Pathogenesis" Society of
Toxicology, 27th Annual Meeting, 1988. Curriculum Vitae Kehrer, J.P. Page 11
5. Chairman, Pulmonary Toxicology session, Society of Toxicology 28th Annual Meeting,
6. Chairman, Society of Toxicology Continuing Education Course on "Free Radical
Toxicology", 29th annual meeting, 1990.
7. Chairman and organizer, Symposium on "Mechanisms of Hypoxic Cell Injury" Society of8. Toxicology, 29th Annual Meeting, 1990. 9. Awards Committee, Society of Toxicology, 1990-1992. 10. Councilor, Mechanisms Specialty Section, Society of Toxicology, 1992-1994. 11. Society of Toxicology Ad hoc Chlorine Working Group. 1994. Work resulted in the
publication of: "Toxicologic principles do not support the banning of chlorine: A Society of Toxicology Position Paper" Fundam. Appl. Toxicol.24: 1-2 (1995).
12. Member, Board of Publications, Society of Toxicology, 1995-1999. 13. Member, Nominating Committee, Oxygen Society, 1995-1996. 14. President, Mechanisms Specialty Section, Society of Toxicology, 1998-1999. 15. Society of Toxicology Media Resource Specialist, 1997-1999. 16. Society of Toxicology World-Wide-Web task force, 1997-200017. Society of Toxicology – elected to Nominating Committee, 200018. Society of Toxicology World-Wide-Web Special Advisory Committee, 2001-2005
19. American Society for Pharmacology and Experimental Therapeutics, elected Chairman of
Miscellaneous Scholarly Activities 1. Rho Chi Faculty Advisor, 1981-1983. 2. Item writer for the National Association of Boards of Pharmacy Licensure Examinations,
3. Co-author (with Daniel M. Kehrer) of "Consumer Drug File"--A syndicated drug information
4. Invited participant, Pharmaceutical Manufacturers Association Coordinated Industry Program
for Pharmacy Faculty, Abbott Laboratories, August 16-27, 1982. Grant and other Review Activities 1. Veterans Administration, Merit Review Board for the Basic Sciences, 1983. 2. Research Corporation Cottrell College Science Grants, 1988, 1989. 3. University of Texas Research Institute, 1987-1990 4. Special Reviewer, NIH Toxicology Study Section, Oct. 1989. 5. Member NIH Toxicology Study Section, July 1991 - June 1995. 6. American Institute of Biological Sciences (for U.S. Army), 1995. 7. Oral Cancer Center Review Panel, NIH, 1996 8. ALTOX NIH Study Section, Ad hoc; 1996, 1997, 1999, 2002 9. External reviewer, Graduate Center for Toxicology, University of Kentucky, April 1996 10. National Science Foundation, 1996 11. John Sealy Memorial Endowment Fund, Univ. Texas Med. Branch Galveston, 1996.
12. Veterans Administration, Pulmonary Merit Review Board, member 1997-1998. 13. Pacific Northwest National Laboratory, Environmental Health Initiative Aug. 1999. 14. Medical Center Research Fund grants, Univ. Kentucky, 200115. Israel Biomedical Research Grant Program reviewer, 2001, 200216. Philip Morris External Research Program reviewer, 2001, 2002. 17. EPA FIFRA Scientific Advisory Panel. 2003-200618. Member, External Advisory Board for the University of Colorado NIEHS Toxicology
Training Grant (grant submitted 5/04).
19. Member, External Advisory Committee for the Department of Pharmacology and
Toxicology, University of Utah, Feb. 2005. Curriculum Vitae Kehrer, J.P. Page 12 PUBLICATIONS
1. Hornemann, U., Kehrer, J.P. and Eggert, J.H.: Pyruvic acid and D-glucose as precursors in
mitomycin biosynthesis by Streptomyces verticillatus. J. Chem. Soc. Chem. Commun. 1045-1046 (1974).
2. Hornemann, U., Kehrer, J.P., Nunez, C.S. and Ranieri, R.L.: D-Glucosamine and L-citrulline,
precursors in mitomycin biosynthesis by Streptomyces verticillatus. J. Amer. Chem. Soc. 96: 320-322 (1974).
3. Hornemann, U., Kehrer, J.P., Nunez, C.S., Ranieri, R.L. and Ho, Y.K.: Precursors in
mitomycin biosynthesis by Streptomyces verticillatus, in "Developments in IndustrialMicrobiology", Vol. 15, pp. 82-92 (1974).
4. Kehrer, J.P. and Autor, A.P.: Age-dependent lipid peroxidation in neonatal rat lung tissue. Arch. Biochem. Biophys.181: 73-81 (1977).
5. Kehrer, J.P. and Autor, A.P.: Changes in the fatty acid composition of rat lung lipids during
development and following age-dependent lipid peroxidation. Lipids12: 596-603 (1977).
6. Kehrer, J.P. and Autor, A.P.: The relationship between fatty acids and lipid peroxidation in
lungs of neonates. Biol. Neonate 34: 61-67 (1978).
7. Kehrer, J.P. and Autor, A.P.: The effect of dietary fatty acids on the composition of adult rat
lung lipids: relationship to oxygen toxicity. Toxicol. Appl. Pharmacol.44: 423-430 (1978).
8. Kehrer, J.P., Haschek, W.M. and Witschi, H.P.: The influence of hyperoxia on the acute
toxicity of paraquat and diquat. Drug Chem. Toxicol. 2: 397-408 (1979).
9. Kehrer, J.P. and Witschi, H.P.: Effects of drug metabolism inhibitors on butylated hydroxy-
toluene-induced pulmonary toxicity in mice. Toxicol. Appl. Pharmacol.53: 333-342 (1980).
10. Kehrer, J.P. and Witschi, H.P.: In vivo collagen accumulation in an experimental model of
pulmonary fibrosis. Exp. Lung Res.1: 259-270 (1980).
11. Kehrer, J.P.: Oxygen-Induced Lung Damage I. Chemistry of oxygen reduction, in "Lectures in
Toxicology", ed. G. Zbinden, Pergamon Press (1981).
12. Kehrer, J.P.: Oxygen-Induced Lung Damage II. Pulmonary oxygen toxicity, in "Lectures in
Toxicology", ed. G. Zbinden, Pergamon Press (1981).
13. Kehrer, J.P. and Witschi, H.P.: The effect of indomethacin, prednisolone, and cis-4-
hydroxyproline on pulmonary fibrosis produced by treatment with butylated hydroxytoluene and oxygen. Toxicology20: 281-288 (1981).
14. Witschi, H.P., Hakkinen, P.J. and Kehrer, J.P.: Modification of lung tumor development in A/J
mice. Toxicology21: 37-45 (1981).
15. Witschi, H.P. and Kehrer, J.P.: Adenoma development in mouse lung following treatment with
possible promoting agents. J. Amer. Coll. Toxicol. 1: 171-184 (1982).
16. Kehrer, J.P.: Collagen production rates following acute lung damage induced by butylated
hydroxytoluene. Biochem. Pharmacol. 31: 2053-2058 (1982). Curriculum Vitae Kehrer, J.P. Page 13
17. Kehrer, J.P. and Autor, A.P.: Unsaturated fatty acids in the postnatally developing rat lung. Lipids18: 50-54 (1983).
18. Haschek, W.M., Reiser, K.M., Klein-Szanto, A.J.P., Kehrer, J.P., Smith, L.H., Last, J.A. and
Witschi, H.P.: Potentiation of butylated hydroxytoluene-induced acute lung damage by oxygen. Cell kinetics and collagen metabolism. Am. Rev. Respir. Dis. 127: 28-34 (1983).
19. Kehrer, J.P.: The effect of BCNU (carmustine) on tissue glutathione reductase activity. Toxicol. Lett. 17: 63-68 (1983).
20. Kehrer, J.P., Pearlman, R. and Smith, M.A.: Direct effects of corticosteroids on in vitro
collagen production by normal and damaged lung tissue. Toxicology 28: 235-246 (1983).
21. Kehrer, J.P. and Paraidathathu, T.: Enhanced oxygen toxicity following pretreatment with
BCNU. Fundam. Appl. Toxicol.4: 760-767 (1984).
22. Kehrer, J.P., Klein-Szanto, A.J.P., Sorensen, E.M.B., Pearlman, R. and Rosner, M.H.:
Enhanced acute lung damage following corticosteroid treatment. Am. Rev. Respir. Dis. 130: 256-261 (1984).
23. Kehrer, J.P. and Dydek, S.T.: Analysis of pulmonary collagen production by HPLC separation
of radiolabeled hydroxyproline and proline. Proc. West. Pharmacol. Soc. 27: 319-322 (1984).
24. Dydek, S.T. and Kehrer, J.P.: Effects of sodium chloride on the HPLC separation of
hydroxyproline and proline. LC 2: 536-538 (1984).
25. Kehrer, J.P.: Collagen synthesis and degradation in acutely damaged mouse lung tissue
following treatment with prednisolone. Biochem. Pharmacol. 34: 2519-2524 (1985).
26. Paraidathathu, T., Combs, A.B. and Kehrer, J.P.: In vivo effects of 1,3-bis(2-chloroethyl)- 1-
nitrosourea and doxorubicin on the cardiac and hepatic glutathione systems. Toxicology35: 113-124 (1985).
27. Kehrer, J.P. and Kacew, S.: Systemically applied chemicals that damage lung tissue. Toxicology 35: 251-293 (1985).
28. Kehrer, J.P. and Klein-Szanto, A.J.P.: Enhanced acute lung damage in mice following
administration of 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res.45: 5707-5713 (1985).
29. Lee, Y-C. C. and Kehrer, J.P.: Increased pulmonary collagen synthesis in mice treated with
cyclophosphamide. Drug Chem. Toxicol.8: 503-512 (1985).
30. Kehrer, J.P., Lee, Y-C.C. and Solem, S.M.: Comparison of in vitro and in vivo rates of
collagen synthesis in normal and damaged lung tissue. Exp. Lung Res. 10: 187-201 (1986).
31. Murphy, M.E. and Kehrer, J.P.: Activities of antioxidant enzymes in the muscle, liver and lung
of chickens with inherited muscular dystrophy. Biochem. Biophys. Res. Commun. 134: 550- 556 (1986).
32. Kehrer, J.P., Lee, Y-C.C. and Smith, R.D.: Effect of intratracheally administered anticancer
drugs on lung hydroxyproline content. Toxicol. Lett. 30: 63-70 (1986).
33. Murphy, M.E. and Kehrer, J.P.: Free radicals: A potential pathogenic mechanism in inherited
muscular dystrophy. Life Sci.39: 2271-2278 (1986). Curriculum Vitae Kehrer, J.P. Page 14
34. Kehrer, J.P., Klein-Szanto, A.J.P., Thurston, D., Lindenschmidt, R.C. and Witschi, H.R.:
O,S,S-Trimethyl phosphorodithioate-induced lung damage in rats and mice. Toxicol. Appl. Pharmacol. 84: 480-492 (1986).
35. Kehrer, J.P.: Oxygen, in "Handbook on Toxicity of Inorganic Compounds", (H.G. Seiler and
H. Sigel, eds.), Marcel Dekker, NY, pp. 505-515 (1987).
36. Kehrer, J.P., Piper, H.M. and Sies, H.: Xanthine oxidase and reoxygenation injury in isolated
perfused rat heart. Free Rad. Res. Commun. 3: 69-78 (1987).
37. Murphy, M.E. and Kehrer, J.P.: Simultaneous measurement of tocopherols and tocopheryl
quinones in tissue fractions using HPLC with redox-cycling electrochemical detection. J. Chromatog. 421, 71-82 (1987).
38. Kehrer, J.P. and Lee, Y-C.C.: Pulmonary hydroxyproline content and production following
treatment of mice with O,S,S- trimethyl phosphorodithioate. Toxicol. Lett. 38: 321-327 (1987).
39. Wright, E.S., Kehrer, J.P., White, D.M. and Smiler, K.L.: Effects of chronic exposure to ozone
on collagen in rat lung. Toxicol. Appl. Pharmacol.92: 445-452 (1988).
40. Kehrer, J.P., Sevanian, A., Trush, M.A., Mossman, B.T. and Smith, M.T.: Free radical
mechanisms in chemical pathogenesis. Toxicol. Appl. Pharmacol.95: 349-362 (1988).
41. Kehrer, J.P., Park, Y. and Sies, H.: Energy-dependence of enzyme release from hypoxic
isolated-perfused rat heart tissue. J. Appl. Physiol.65: 1855-1860 (1988).
42. Murphy, M.E. and Kehrer, J.P.: Increased oxidation of tocopherols in chickens with inherited
muscular dystrophy, in "Oxygen Radicals in Biology and Medicine", Vol. 49, The Proceedingsof the Fourth International Congress on Oxygen Radicals, (M. G. Simic, K.A. Taylor, J.F. Ward, and C. von Sonntag, eds.), Plenum, New York, pp. 611-614 (1988).
43. Park, Y., Smith, R.D., Combs, A.B. and Kehrer, J.P.: Prevention of acetaminophen-induced
hepatotoxicity by dimethyl sulfoxide. Toxicology52: 165-175 (1988).
44. Kehrer, J.P.: Cardiac cell breakdown at reoxygenation: Absence of changes in xanthine
oxidase and effects of calcium concentration, in "The Role of Oxygen Radicals inCardiovascular Diseases", (A. L'Abbate and F. Ursini, eds.), Kluwer Academic Publishers,Dordrecht, pp. 71-89 (1988).
45. Murphy, M.E. and Kehrer, J.P.: Lipid peroxidation inhibitory factors in liver and muscle of rat,
mouse and chicken. Arch. Biochem. Biophys. 268: 585-593 (1989).
46. Murphy, M.E. and Kehrer, J.P.: Oxidative stress and muscular dystrophy. Chemico-biol.Interact. 69: 101-173 (1989).
47. Kehrer, J.P.: Concepts related to the study of reactive oxygen and cardiac reperfusion injury. Free Radical Res. Commun.5: 305-314 (1989).
48. Murphy, M.E. and Kehrer, J.P.: Oxidation state of tissue thiol groups and content of protein
carbonyl groups in chickens with inherited muscular dystrophy. Biochem. J. 260: 359-364 (1989).
49. Murphy, M.E. and Kehrer, J.P.: Altered contents of tocopherols in chickens with inherited
muscular dystrophy. Biochem. Med. Metab. Biol. 41: 234-245 (1989). Curriculum Vitae Kehrer, J.P. Page 15
50. Starnes, J.W., Cantu, G., Farrar, R.P. and Kehrer, J.P.: Skeletal muscle lipid peroxidation in
exercised and food restricted rats during aging. J. Appl. Physiol. 67: 69-75 (1989).
51. Kehrer, J.P. and Starnes, J.W.: Models and markers used to study cardiac reperfusion injury. Pharmacol. Therap. 44: 123-145 (1989).
52. Kehrer, J.P.: Bleomycin and cyclophosphamide toxicity in mice with damaged lung tissue. Toxicology 57: 69-82 (1989).
53. Ziegler, D.M. and Kehrer, J.P.: Oxygen radicals and drugs: in vitro measurements. Methods inEnzymology186: 621-626 (1990).
54. Park, Y. and Kehrer, J.P.: Protection against hypoxic injury in isolated-perfused rat heart by
ruthenium red. J. Pharmacol. Expt. Ther. 253: 628-635 (1990).
55. Kehrer, J.P. and DiGiovanni, J.: Comparison of lung injury induced in four strains of mice by
butylated hydroxytoluene. Toxicol. Lett. 52: 55-61 (1990).
56. Kehrer, J.P.: Commentary on the pulmonary toxicity of inhaled and intravenous talc. Toxicol.Lett. 52: 117-119 (1990).
57. Kehrer, J.P.: Commentary on the production of alveolar macrophage-derived growth regulating
proteins in response to lung injury. Toxicol. Lett. 54: 1-2 (1990).
58. Kehrer, J.P., Jones, D.P., Lemasters, J.J., Farber, J.L. and Jaeschke, H.: Mechanisms of
hypoxic cell injury. Toxicol. Appl. Pharmacol. 106: 165-178 (1990).
59. Kehrer, J.P. and Park, Y.: Purity of ruthenium red used in biochemical research. J. Pharmacol.Meth. 25: 179-183 (1991).
60. Bowles, D.K., Torgan, C.E., Ebner, S., Kehrer, J.P., Ivy, J.L. and Starnes, J.W.: Effects of
acute, submaximal exercise on skeletal muscle vitamin E. Free Rad. Res. Commun. 14: 139- 143 (1991).
61. Kehrer, J.P. and Park, Y.: Oxidative stress during hypoxia in isolated-perfused rat heart. Adv.Exp. Med. Biol. 283: 299-304 (1991).
62. Smith, R.D. and Kehrer, J.P.: Cooxidation of cyclophosphamide as an alternative pathway for
its bioactivation and lung toxicity. Cancer Res. 51: 542-548 (1991).
63. Park, Y. and Kehrer, J.P.: Oxidative changes in hypoxic-reoxygenated rabbit heart: A
consequence of hypoxia rather than reoxygenation. Free Rad. Res. Commun. 14: 179-185 (1991).
64. Park, Y., Kanekal, S. and Kehrer, J.P.: Oxidative changes in hypoxic rat heart tissue. Am. J.Physiol. 260: H1395-H1405 (1991).
65. Fraiser, L., Kanekal, S. and Kehrer, J.P.: Cyclophosphamide toxicity: characterizing and
avoiding the problem. Drugs42: 781-795 (1991).
66. Seiler, K.S., Kehrer, J.P. and Starnes, J.W.: Effect of perfusion pressure at reoxygenation on
reflow and function in isolated rat hearts. Am. J. Physiol.262: H1029-H1035 (1992). Curriculum Vitae Kehrer, J.P. Page 16
67. Kehrer, J.P. and Murphy, M.E.: Free radicals and muscular dystrophy. in Free RadicalMechanisms of Tissue Injury (C.V. Smith and M. Moslen, eds) CRC Press, Boca Raton, pp. 189-202 (1992).
68. Palamanda, J.R. and Kehrer, J.P.: Inhibition of protein carbonyl formation and lipid
peroxidation by glutathione in rat liver microsomes. Arch. Biochem. Biophys. 293: 103-109 (1992).
69. Kehrer, J.P. and Paraidathathu, T.: The use of fluorescent probes to assess oxidative processes
in isolated-perfused rat heart tissue. Free Rad. Res. Commun. 16: 217-225 (1992).
70. Kanekal, S., Fraiser, L. and Kehrer, J.P.: Pharmacokinetics, metabolic activation and lung
toxicity of cyclophosphamide in C57/Bl6 and ICR mice. Toxicol. Appl. Pharmacol. 114: 1-8 (1992).
71. Spitz, D.R., Kinter, M.T., Kehrer, J.P. and Roberts, R.J.: The effect of monosaturated and
polyunsaturated fatty acids on O2-toxicity in cultured cells. Pediatr. Res. 32: 366-372 (1992).
72. Paraidathathu, T., de Groot, H. and Kehrer, J.P.: Production of reactive oxygen by
mitochondria from normoxic and hypoxic rat heart tissue. Free Rad.Biol. Med.13: 289-297 (1992).
73. Fraiser, L. and Kehrer, J.P.: Murine strain differences in metabolism and bladder toxicity of
cyclophosphamide. Toxicology75: 257-272 (1992).
74. Kanekal, S. and Kehrer, J.P.: Evidence for peroxidase-mediated metabolism of
cyclophosphamide. Drug Metab. Dispos.21: 37-42 (1993).
75. Palamanda, J.R. and Kehrer, J.P.: Involvement of vitamin E and protein thiols in the inhibition
of microsomal lipid peroxidation by glutathione. Lipids 28: 427-431 (1993).
76. Kehrer, J.P.: Free radicals as mediators of tissue injury and disease. Crit. Rev. Toxicol. 23: 21-
77. Fraiser, L. and Kehrer, J.P.: Effect of indomethacin, aspirin, nordihydroguairetic acid, and
piperonyl butoxide on cyclophosphamide-induced bladder damage. Drug Chem. Toxicol.16: 117-133 (1993).
78. Kehrer, J.P., Paraidathathu, T. and Lund, L.G.: Effects of oxygen deprivation on cardiac redox
systems. Proc. West. Pharmacol. Soc. 36: 45-52 (1993).
79. Kehrer, J.P.: Systemic pulmonary toxicity, in "General and Applied Toxicology. Volume 1:
Basic, Route and Organ Toxicity", (B. Ballantyne, T. Marrs, and P. Turner, eds.), StocktonPress, New York, pp. 537-554 (1993).
80. Kanekal, S. and Kehrer, J.P.: Metabolism of cyclophosphamide by lipoxygenases. DrugMetab. Dispos. 22: 74-78 (1994).
81. Kehrer, J.P. and Smith, C.V.: Free radicals in biology: sources, reactivities and roles in the
etiology of human diseases. in Natural Antioxidants in Human Health and Disease, (B. Frei,ed.) Academic Press, pp.25-62 (1994).
82. Kehrer, J.P. and Lund, L.G.: Cellular reducing equivalents and oxidative stress. Free Rad. Biol.Med. 17: 65-75 (1994). Curriculum Vitae Kehrer, J.P. Page 17
83. Paraidathathu, T., Palamanda, J. and Kehrer, J.P.: Modulation of rat heart mitochondrial
function and the production of reactive oxygen by vitamin E deficiency. Toxicology90: 103- 114 (1994).
84. Lund, L.G., Paraidathathu, T. and Kehrer, J.P.: Reduction of glutathione disulfide and the
maintenance of reducing equivalents in hypoxic hearts after the infusion of diamide. Toxicology 93: 249-262 (1994).
85. Stevenson, D., Kehrer, J.P., Kolaja, K.L., Walborg, E.F.Jr. and Klaunig, J.E.: Effect of dietary
antioxidant vitamins on dieldrin-induced hepatotoxicity in mice. Toxicol. Lett. 75: 177-183 (1995).
86. Perry, C.S., Liu, X.L., Lund, L.G., Whitman, C.S. and Kehrer, J.P.: Differential toxicities of
cyclophosphamide and its glutathione metabolites to A549 cells. Toxicol. In Vitro 9: 21-26 (1995).
87. Ramu, K., Fraiser, L.H., Mamiya, B., Ahmed, T., and Kehrer, J.P.: Acrolein mercapturates:
Synthesis, characterization, and assessment of their role in the bladder toxicity of cyclophosphamide. Chem. Res. Toxicol. 8: 515-524 (1995).
88. Liu, H. and Kehrer, J.P.: The reduction of glutathione disulfide produced by t-butyl
hydroperoxide in respiring mitochondria. Free Rad. Biol. Med. 20: 433-442 (1996).
89. Seiler, K.S., Kehrer, J.P. and Starnes, J.W.: Exogenous glutathione attenuates stunning
following intermittent hypoxia in isolated rat hearts. Free Rad. Res. 24: 115-122 (1996).
90. Ramu, K., Perry, C.S., Ahmed, T., Pakenham, G. and Kehrer, J.P.: Studies on the basis for the
toxicity of acrolein mercapturates. Toxicol. Appl. Pharmacol. 140: 487-498 (1996).
91. Kehrer, J.P. and Margolin, S.B.: Pirfenidone diminishes cyclophosphamide-induced lung
fibrosis in mice. Toxicol. Lett. 90: 125-132 (1997).
92. Kehrer, J.P.: Mechanisms: Free radicals and reactive oxygen species. In General Principles,Toxicokinetics, and Mechanisms of Toxicity, (J.A. Bond, ed.) Elsevier, Vol. 1 ofComprehensive Toxicology, pp. 275-301 (1997).
93. Ramu, K. and Kehrer, J.P.: The pulmonary toxicity of chemotherapeutic agents. In Toxicologyof the Respiratory Tract, (R. Roth, ed.) Elsevier, Vol. 8 of Comprehensive Toxicology, pp. 521-541 (1997).
94. Horton, N.D., Mamiya, B.M. and Kehrer, J.P.: Relationships between cell density, glutathione
and proliferation of A549 human lung adenocarcinoma cells treated with acrolein. Toxicology 122: 111-122 (1997).
Bojes, H.K., Datta, K., Xu, J., Chin, A., Simonian, P., Nuñez, G. and Kehrer, J.P.: Bcl-xL
overexpression attenuates glutathione depletion in FL5.12 cells following IL-3 withdrawal. Biochem. J. 325: 315-319 (1997).
Robertson, J.D., Starnes, J.W. and Kehrer, J.P.: Cosubstrates involved in the reduction of cytosolic glutathione disulfide in rat heart. Toxicology 124: 11-19 (1997).
Robertson, J.D., Datta, K. and Kehrer, J.P.: Bcl-xL overexpression restricts heat-induced
apoptosis and influences hsp70, bcl-2 and bax protein levels in FL5.12 cells. Biochem. Biophys. Res. Commun. 241: 164-168 (1997). Curriculum Vitae Kehrer, J.P. Page 18
Swift, J.N., Kehrer, J.P., Seiler, K.S. and Starnes, J.W.: Changes in vitamin E levels in rat skeletal muscle and liver after exercise. Int. J. Sport Nutr.8: 105-112 (1998).
Datta, K., Chin, A., Ahmed, T., Qing, W-G., Powell, K.L., Simhambhatla, P., MacLeod, M.C. and Kehrer, J.P.: Mixed effects of 2,6-dithiopurine against cyclophosphamide-mediated bladder and lung toxicity in mice. Toxicology125: 1-11 (1998).
100. Bojes, H.K., Suresh, P.K., Mills, E.M., Spitz, D.R. and Kehrer, J.P.: Bcl-2 and bcl-xL in
peroxide resistant A549 and U87MG cells. Toxicolog. Sci 42: 109-116 (1998).
101. Datta, K., Biswal, S.S., Xu, J., Towndrow, K.M., Feng, X. and Kehrer, J.P.: A relationship
between 5-lipoxygenase activating protein (FLAP) and bcl-x expression in murine pro B-
lymphocytic FL5.12 cells. J. Biol. Chem. 273: 28163-28169 (1998).
102. Bojes, H.K., Feng, X., Kehrer, J.P. and Cohen, G.M.: Apoptosis in hematopoietic cells
(FL5.12) caused by interleukin-3 withdrawal: relationship to caspase activity and the loss of glutathione. Cell Death Different. 6: 61-70 (1999).
103. Kehrer, J.P.: Systemic pulmonary toxicity, in General and Applied Toxicology, 2nd Edition
(B. Ballantyne, T. Marrs, and Syversen, eds.), MacMillan Press, New York, pp. 721-736(volume 2) (1999).
104. Horton, N.D., Biswal, S.S., Corrigan, L.L., Bratta, J. and Kehrer, J.P.: Acrolein causes IκB-
independent decreases in NF-κB activation in human lung adenocarcinoma (A549) cells
through the formation of p50 adducts. J. Biol. Chem. 274: 9200-9206 (1999).
105. Datta, K., Biswal, S.S. and Kehrer, J.P.: The 5-lipoxygenase activating protein (FLAP)
inhibitor, MK886, induces apoptosis independent of FLAP. Biochem. J.340: 371-375 (1999).
106. Robertson, J.D., Datta, K., Biswal, S.S. and Kehrer, J.P.: Hsp70 antisense oligomers enhance
proteasome inhibitor-induced apoptosis. Biochem. J. 344: 477-485 (1999).
107. Biswal, S.S., Datta, K., Shaw, S.D., Feng, X., Robertson, J.D. and Kehrer, J.P.: Glutathione
oxidation and mitochondrial depolarization as mechanisms of nordihydroguaiaretic acid-induced apoptosis in lipoxygenase-deficient FL5.12 cells. Toxicolog. Sci.53: 77-83 (2000).
108. Kehrer, J.P.: Reductive stress, in Encyclopedia of Stress, (G. Fink, ed.) 3: 327-333 Academic
109. Kehrer, J.P. and Biswal, S.S.: The molecular effects of acrolein. Toxicolog. Sci. 57: 6-15
110. Kehrer, J.P.: Cause-effect of oxidative stress and apoptosis. Teratology62: 235-236 (2000).
111. Kehrer, J.P.: The Haber-Weiss reaction and mechanisms of toxicity. Toxicology 149: 43-50
112. Biswal, S.S., Datta, K., Acquaah-Mensah, G.K. and Kehrer, J.P.: Changes in ceramide,
sphingomyelin and p53 following fludarabine treatment of human chronic B-cell leukemia cells. Toxicology154: 45-53 (2000).
113. Kehrer, J.P. and Mirsalis, J.: Professional toxicology societies: web-based resources. Toxicology 157: 67-76 (2001). Curriculum Vitae Kehrer, J.P. Page 19
114. Biswal, S.S., Datta, K. and Kehrer, J.P.: Association between bcl-x and 5-lipoxygenase
activating protein (FLAP) levels in IL-3-dependent FL5.12 cells. Toxicology 160: 97-103 (2001).
115. Kehrer, J.P., Biswal, S.S., La, E., Thuillier, P., Datta, K., Fischer, S.M. and and Vanden
Heuvel, J.P.: Inhibition of peroxisome proliferator activated receptor alpha (PPARα) by
MK886. Biochem. J. 356: 899-906 (2001). For the 12 months ending November 2002 this was the most downloaded regular research paper from the Biochem. J. 5079 downloads.
116. Datta, K., Kern, J.C., Biswal, S.S. and Kehrer, J.P.: Proteolysis and the loss of bcl-x in
FL5.12 cells undergoing apoptosis induced by MK886. Toxicol. Appl. Pharmacol.174: 273- 281 (2001).
117. Acquaah-Mensah, G.K., Leslie, S.W. and Kehrer, J.P.: Acute exposure of cerebellar granule
neurons to ethanol suppresses stress-activated protein kinase-1 and concomitantly induces AP-1. Toxicol. Appl. Pharmacol.175: 10-18 (2001).
118. Biswal, S., Acquaah-Mensah, G., Datta, K., Wu, X. and Kehrer, J.P.: Inhibition of cell
proliferation and AP-1 activity by acrolein in human A549 lung adenocarcinoma cells due to thiol imbalance and covalent modifications. Chem. Res. Toxicol. 15:180-186 (2002).
119. Tang, D.G., La, E., Kern, J. and Kehrer, J.P.: Fatty acid oxidation and signaling in apoptosis. Biological Chem. 383, 425-442 (2002).
120. Kern, J.C. and Kehrer, J.P.: Acrolein-induced cell death: a caspase-influenced decision
between apoptosis and oncosis/necrosis. Chemico-Biol. Interact.139, 79-95 (2002).
121. Acquaah-Mensah, G.K., Kehrer, J.P. and Leslie, S.W.: Altered cerebellar transcriptional
regulation in a rat fetal alcohol syndrome model. J. Pharmacol. Exptl. Therap. 301: 277-283(2002).
122. Thuillier, P., Brash, A.R., Kehrer, J.P., Stimmel, J.B., Leesnitzer, L.M., Yang, P., Newman,
R.A. and Fischer, S.M.: Inhibition of PPAR-mediated keratinocyte differentiation by lipoxygenase inhibitors. Biochem. J.366, 901-910 (2002).
123. La, E., Kern, J.C., Atarod, E.B. and Kehrer, J.P.: Fatty acid release and oxidation in
lipoxygenase inhibitor-induced apoptosis. Toxicol. Lett. 138, 193-203 (2003).
124. Biswal, S., Maxwell, T., Rangasamy, T. and Kehrer, J.P.: Modulation of benzo[a]pyrene-
induced p53 DNA activity by acrolein. Carcinogenesis 24, 1401-1406 (2003).
125. Tong, Z., Wu, X. and Kehrer, J.P.: Increased expression of the lipocalin 24p3 as an apoptotic
mechanism for MK886. Biochem. J. 372, 203-210 (2003).
126. Wu, X. Biswal, S.S. and Kehrer, J.P.: Roles of 5-lipoxygenase activating protein in cell
proliferation and apoptosis. Cell Biol. Toxicol. 19, 135-143 (2003).
127. Watson, W.H., Yang, X., Choi, Y.E., Jones, D.P. and Kehrer, J.P.: Thioredoxin and its role in
toxicology. Toxicolog. Sci. 78, 3-14 (2004).
128. Atarod, E. B. and Kehrer, J.P.: Dissociation of oxidant production by peroxisome proliferator
activated receptor ligands from cell death in human cell lines. Free Rad. Biol. Med. 37, 36-47 (2004). Curriculum Vitae Kehrer, J.P. Page 20
129. Kern, J.C. and Kehrer, J.P.: Free radicals and apoptosis: relationships with glutathione,
thioredoxin and the bcl family of proteins. Frontiers in Bioscience10, 000-000 (2005).
130. Yang, X., Wu, X., Choi, Y.E., Kern, J.C. and Kehrer, J.P.: Effect of acrolein and glutathione
depleting agents on thioredoxin. Toxicology 204, 209-218 (2004).
131. Tong, Z., Wu, X., Ovcharenko, D., Zhu, J., Chen, C-S. and Kehrer, J.P.: Neutrophil gelatinase
associated lipocalin as a survival factor. (submitted).
132. Tong, Z., Wu, X., and Kehrer, J.P.: Inhibition of Akt by lipoxygenase inhibitors that induce
133. Tang, D.G. and Kehrer, J.P.: Carcinogenesis – Balance between apoptosis and survival
pathways. In "Apoptosis, Cell Signaling, and Human Disease: Molecular Mechanisms, TheHuman Press, Inc., R. Srivastava, editor. (in press, 2005).
134. Kehrer, J.P.: Reductive stress, in Encyclopedia of Stress, (G. Fink, ed., 2nd edition) Elsevier,
Curriculum Vitae Kehrer, J.P. Page 21 ABSTRACTS
Kehrer, J.P. and Autor, A.P.: Age-dependent lipid peroxidation in neonatal rat lungs. Fed. Proc. 35: 1402, #234 (1976).
Kehrer, J.P. and Autor, A.P.: Alterations in the fatty acid composition of lung phospholipids and triglycerides following age-dependent lipid peroxidation in neonatal rat lungs. Toxicol. Appl. Pharmacol.41: 184, 1977.
Kehrer, J.P. and Autor, A.P.: Triglycerides as a specific substrate for age-dependent lipid peroxidation in neonatal rat lungs. Fed. Proc.36: 983,#3761, 1977.
Kehrer, J.P. and Autor, A.P.: Fatty acid desaturase activity and the incorporation of poly- unsaturated fatty acids into lipids of the postnatally developing rat lung. Fed. Proc.37: 719, #2654, 1978.
5. Kehrer, J.P., Haschek, W. and Witschi, H.P.: Peracute toxicity of paraquat and diquat in 100%
oxygen. Toxicol. Appl. Pharmacol. 48: A59, 1979.
6. Kehrer, J.P. and Witschi, H.P.: The role of metabolism in the pulmonary toxicity of butylated
hydroxytoluene. Fed. Proc. 38: 582, #1872, 1979.
7. Kehrer, J.P. and Witschi, H.P.: In vivo collagen synthesis in an experimental model of
pulmonary fibrosis. Fed. Proc.39: 364, #492, 1980.
8. Kehrer, J.P. and Witschi, H.P.: The effect of indomethacin and prednisolone on pulmonary
fibrosis produced by treatment with butylated hydroxytoluene and oxygen. The Toxicologist 1: 56, #203, 1981.
9. Kehrer, J.P. In vitro rates of collagen synthesis in mouse lung tissue following the
administration of butylated hydroxytoluene. The Toxicologist 2: 187, #653, 1982.
10. Kehrer, J.P.: The direct effect of prednisolone on collagen synthesis in acutely damaged lung
tissue. Texas Pharmacologists (1982).
11. Kehrer, J.P.: Enhanced acute lung damage following the administration of corticosteroids. The Toxicologist 3: 109 #435 (1983).
12. Kehrer, J.P.: The inhibition of tissue glutathione reductase activity by BCNU. Assoc. Mex.
13. Kehrer, J.P.: The effect of BCNU-treatment on damaged lung tissue. The Toxicologist4: 57,
14. Paraidathathu, T., Combs, A.B., and Kehrer, J.P.: BCNU-enhanced doxorubicin toxicity. TheToxicologist4: 169, #674 (1984).
15. Kehrer, J.P. and Murphy, M.A.: Effect of BCNU on acetaminophen-induced hepatotoxicity. Fed. Proc. 43: 935, #3802 (1984).
16. Murphy, M.E. and Kehrer, J.P.: Antioxidant enzyme activities and fluorescent compounds in
normal and dystrophic chicken muscle. Texas Pharmacologists, 1985
17. Smith, R.D. and Kehrer, J.P.: The hepatotoxic effects of a combination of acetaminophen and
1,3-bis(2-chloroethyl)-1-nitrosourea in mice. Texas Pharmacologists, 1985. Curriculum Vitae Kehrer, J.P. Page 22
18. Kehrer, J.P.: Collagen metabolism in normal and damaged mouse lung tissue following
treatment with prednisolone. The Toxicologist 5: 34, #136 (1985).
19. Lee, Y-C.C. and Kehrer, J.P.: In vivo versus in vitro rates of pulmonary collagen synthesis. Fed. Proc. 44: 1063, #3813 (1985).
20. Smith, R.D. and Kehrer, J.P.: The hepatotoxic effects of a combination of BCNU and
acetaminophen in mice. The Toxicologist6: 154, #621 (1986).
21. Murphy, M.E. and Kehrer, J.P.: Age-dependent changes in antioxidant enzyme activities in four
tissues of normal and muscular dystrophic chickens.The Toxicologist6: 151, #610 (1986).
22. Kehrer, J.P. and Klein-Szanto, A.J.P.: Lung damage in mice treated with O,S,S-trimethyl
phosphorodithioate. Fed. Proc. 45: 743 #3415 (1986).
23. Kehrer, J.P.: Lung damage and collagen synthesis after intratracheal anticancer drugs or
parenteral cyclophosphamide. Europ. Soc. Toxicol. (1986).
24. Kehrer, J.P. and Murphy, M.E.: Elevated antioxidant enzyme activities in four tissues of
normal and dystrophic chickens: Evidence for oxidative stress? Soc. Free Rad. Res. (1986).
25. Kehrer, J.P. and Sies, H.: Absence of changes in xanthine oxidase activity following hypoxia
and reoxygenation in isolated perfused rat heart tissue. Soc. Free Rad. Res. (1986).
26. Kehrer, J.P. and Sies, H.: Inhibition of enzyme release from isolated perfused rat heart upon
reoxygenation by cyanide and cystamine. The Toxicologist7: 93, #372 (1987).
27. Wright, E.S., Kehrer, J.P., White, D.M. and Smiler, K.L.: Effects of chronic exposure to ozone
on collagen metabolism in rat lung. The Toxicologist7: 186, #744 (1987).
28. Park, Y.J., Smith, R.D., Combs, A.B. and Kehrer, J.P.: Effects of BCNU on acetaminophen
biotransformation and glutathione-S-transferase. The Toxicologist 7: 116, #465 (1987).
29. Murphy, M.E. and Kehrer, J.P.: Tocopherols and enzymatic membrane antioxidants in avian
muscular dystrophy. Fed. Proc.46: 1151, #4867 (1987).
30. Kehrer, J.P. and Murphy, M.E.: Tocopherol metabolism in liver and muscle tissue from
normal and dystrophic chickens. "Role of Oxygen Radicals and Antioxidants in Cancer andAging", Satellite meeting of the Society for Free Radical Research, Feb. 1987.
31. Park, Y., Smith, R.D., Combs, A.B. and Kehrer, J.P.: Effects of BCNU on acetaminophen
toxicity and glutathione-S-transferase. Texas Pharmacologists, May 1987.
32. Murphy, M.E. and Kehrer, J.P.: Analysis of tocopherols and tocopheryl quinones by HPLC
with redox cycling electrochemical detection. The Pharmacologist 29: 209, #551 (1987).
33. Murphy, M.E. and Kehrer, J.P.: Increased oxidation of tocopherols in chickens with inherited
muscular dystrophy. Fourth International Congress on Oxygen Radicals (Invited abstract, pp. 48-51, 1987).
34. Park, Y. and Kehrer, J.P.: Energy-dependent enzyme release from hypoxic heart tissue
perfused with calcium-free medium. The Toxicologist 8: 190, #755 (1988). Curriculum Vitae Kehrer, J.P. Page 23
35. Smith, R.D. and Kehrer, J.P.: Pretreatment with cyclophosphamide does not protect against the
lung damage and fibrosis of a second dose. The Toxicologist8: 3, #11 (1988).
36. Kehrer, J.P. and Murphy, M.E.: Tocopheryl quinones in genetic muscular dystrophy in
chickens. Soc. Free Rad. Res. (1988).
37. Kehrer, J.P.: Increased bleomycin toxicity in mice with butylated hydroxytoluene-induced lung
damage. FASEB J.2: A1559, #7338 (1988).
38. Kehrer, J.P. and Murphy, M.E.: Factors inhibiting lipid peroxidation in liver and muscle of rat,
mouse and chicken. The Toxicologist 9: 156, #624 (1989).
39. Park, Y. and Kehrer, J.P.: Oxidative changes in hypoxic-reoxygenated rat myocardium. TheToxicologist9: 277, #1111 (1989).
40. Smith, R.D. and Kehrer, J.P.: Lung injury and fibrosis in mice given one or two doses of
cyclophosphamide. The Pharmacologist 31: 176, #310 (1989).
41. Kehrer, J.P. and Park, Y.: Oxidative stress during hypoxia in isolated-perfused rat heart. 4th
International Symposium on Biological Reactive Intermediates. (1990)
42. Palamanda, J. and Kehrer, J.P.: Inhibition of lipid and protein oxidation in rat liver microsomes
by glutathione. The Toxicologist10: 24, #96 (1990).
43. Fraiser, L. and Kehrer, J.P.: Metabolism of bleomycin by normal and damaged mouse lung
tissue. The Toxicologist10: 99, #395 (1990).
44. Kehrer, J.P. and Park, Y.: Protection by ruthenium red against hypoxia-reoxygenation injury in
rat myocardium. The Toxicologist10: 34, #136 (1990).
45. Bowles, D.K., Torgan, C.E., Ebner, S., Kehrer, J.P., Ivy, J.L. and Starnes, J.W.: Effects of acute,
submaximal exercise on skeletal muscle vitamin E. Med. Sci. Sports Ex.22: S74 (1990).
46. Kehrer, J.P. and Smith, R.D.: Cyclophosphamide cooxidation by prostaglandin H synthase: an
alternative bioactivation mechanism. Proc. West. Pharmacol. Soc.34: 524 (1991).
47. Palamanda, J. and Kehrer, J.P.: Inhibition of iron-ascorbate stimulated lipid peroxidation in rat
liver microsomes by purine and pyrimidine triphosphates.The Toxicologist11: 215 #799 (1991).
48. Kanekal, S. and Kehrer, J.P.: Arachidonic acid-dependent metabolic activation of
cyclophosphamide. The Toxicologist11: 258 #978 (1991).
49. Paraidathathu, T., de Groot, H. and Kehrer, J.P.: Production of reactive oxygen species (ROS)
by rat heart mitochondria: effect of calcium and ischemia. The Toxicologist11: 98 #308 (1991).
50. Fraiser, L. and Kehrer, J.P.: Evidence for a role of prostaglandin H synthase (PHS) in
cyclophosphamide toxicity in mice. The Toxicologist11: 257 #977 (1991).
51. Seiler, K.S., Kehrer, J.P. and Starnes, J.W.: Increased perfusion pressure improves recovery in
hypoxic rat heart. FASEB J. 5: A1045 #3919 (1991).
52. Kanekal, S. and Kehrer, J.P.: Strain differences in cyclophosphamide-induced pulmonary
fibrosis. FASEB J. 5: A1569 #6957 (1991). Curriculum Vitae Kehrer, J.P. Page 24
53. Spitz, D.R., Kinter, M.T., Kehrer, J.P., Adams, D.T., Sherman, C.M. and Roberts, R.J.: The
effect of unsaturated fatty acids linoleic or eicospentaenoic acid, on O2-toxicity in cultured
cells. Pediatr. Res. 29: 331A #1967 (1991).
54. Palamanda, J. and Kehrer, J.P.: Inhibition of microsomal lipid peroxidation by glutathione and
nucleoside triphosphates. The Toxicologist12: 175 #622 (1992).
55. Fraiser, L. and Kehrer, J.P.: Metabolism and bladder toxicity of cyclophosphamide in mice. The Toxicologist12: 289 #1115 (1992).
56. Paraidathathu, T. and Kehrer, J.P.: Production of reactive oxygen species by cardiac
mitochondria and in isolated-perfused rat heart tissue. The Toxicologist12: 74 #196 (1992).
57. Kanekal, S., Fraiser, L., Davis, J. and Kehrer, J.P.: Metabolism of cyclophosphamide (CP) by
peroxidases. The Toxicologist12: 330 #1279 (1992).
58. Seiler, K.S., Kehrer, J.P. and Starnes, J.W.: Exogenous glutathione (GSH) prevents
myocardial stunning following intermittent hypoxia in isolated rat hearts. FASEB J.6: A1341 #2347 (1992).
59. Paraidathathu, T., Lund, L.G. and Kehrer, J.P.: Changes in high energy phosphates,
glutathione, and pyridine nucleotides in hypoxic heart tissue exposed to diamide. The Toxicologist13: 119 #382 (1993).
60. Fraiser, L., Skarovsky, C. and Kehrer, J.P.: Bioactivation of a glutathione-acrolein conjugate to
bladder toxic species. The Toxicologist13: 226 #836 (1993).
61. Kehrer, J.P. and Kanekal, S.: Arachidonic acid (AA)-mediated metabolism and cytotoxicity of
cyclophosphamide (CP) in NCI H358 pneumocytes. The Toxicologist13: 384 #1504 (1993).
62. Kanekal, S. and Kehrer, J.P.: Metabolism of cyclophosphamide (CP) by soybean
lipoxygenases. The Toxicologist13: 385 #1505 (1993).
63. Kehrer, J.P.: Effects of oxygen deprivation in cardiac injury. Proc. West. Pharmacol. Soc.
64. Kanekal, S. and Kehrer, J.P.: Prostaglandin H synthase (PHS) inhibitors decrease the
antineoplastic effect of cyclophosphamide (CP) in vivo.FASEB J.7: A690, #3988 (1993).
65. Kehrer, J.P. and Lund, L.G.: Pyridine nucleotides and the reduction of GSSG in hypoxic heart
tissue exposed to diamide. Free Rad. Biol. Med.15: 520, #7:19 (1993).
66. Lund, L.G., Paraidathathu, T. and Kehrer, J.P.: Reduction of glutathione disulfide (GSSG) and
the maintenance of reducing equivalents in hypoxic rat hearts after infusion with diamide. The Toxicologist 14: 170, #611 (1994).
67. Perry, C.S., Liu, X.L., Lund, L.G. and Kehrer, J.P.: The effect of cyclophosphamide (CP) and
its metabolites on the growth of cultured A549 cells. The Toxicologist 14: 113, #370 (1994).
68. Mulumudi, M. and Kehrer, J.P.: Possible roles for 3-oxopropyl (3-oxoPrMCA) and 3-
hydroxypropyl (3-hydroxyPrMCA) mercapturic acids in cyclophosphamide (CP)-induced bladder damage. The Toxicologist 14: 113, #369 (1994). Curriculum Vitae Kehrer, J.P. Page 25
69. Stevenson, D.E., Kehrer, J.P., Kolaja, K.L., Walborg, E.F. and Klaunig, J.E.: Effects of dietary
antioxidants on dieldrin-induced hepatic effects in B6C3F1 mice. 7th International Conference
70. Lund, L.G., Liu, H. and Kehrer, J.P.: Glutathione disulfide (GSSG) reduction after t-butyl
hydroperoxide (tBOOH)-induced oxidative stress in isolated hepatic mitochondria. FASEB J. 8: A672, #3899 (1994).
71. Liu, H.L. and Kehrer, J.P.: Reduction of glutathione disulfide in oxidatively stressed respiring
rat liver mitochondria. The Toxicologist 15: 280 #1500 (1995).
72. Kehrer, J.P., Ramu, K., and Mamiya, B.: Synthesis and characterization of the mercapturic
acids of acrolein. The Toxicologist 15: 267 #1430 (1995).
73. Ramu, K., Ahmed, T., Fraiser, L. and Kehrer, J.P.: Acrolein mercapturates and the bladder
toxicity of cyclophosphamide. The Toxicologist 15: 304 #1628 (1995).
74. Perry, C.S. and Kehrer, J.P.: Effects of glutathione-acrolein conjugates on the thiol status of
A549 cells. The Toxicologist 15: 304 #1627 (1995).
75. Liu, X-L., Perry, C.S., Lund, L.G. and Kehrer, J.P.: Effect of cyclophosphamide and its
metabolites on growth of cultured A549 cell and protective effects of glutathione and N- acetylcysteine. Acta Pharmacologica Sinica 16: 75 (1995).
76. Kehrer, J.P., Awasthi, S., Spitz, D.R. and Smith, C.V.: Peroxide toxicity and bcl-2 in human
tumor cell lines. Free Rad. Biol. Med. abstract book (1995).
77. Ramu, K., Perry, C.S., Ahmed, T., Pakenham, G. and Kehrer, J.P.: Mechanisms of acrolein
mercapturate toxicity. Fundam. Appl. Toxicol. 30: 284 #1455 (1996).
78. Kehrer, J.P., Suresh, P.K. and Spitz, D.R.: Peroxide resistance and bcl-2 expression in human
tumor cell lines. Fundam. Appl. Toxicol. 30: 242 #1241 (1996).
79. Suresh, P.K., Awasthi, S., Smith, C.V. and Kehrer, J.P.: Peroxide toxicity and bcl-2 in A549
cells. Fundam. Appl. Toxicol. 30: 245, #1254 (1996).
80. Swift, J.N., Seiler, K.S., Kehrer, J.P. and Starnes, J.W.: Depletion and resynthesis of
antioxidants following exercise. Med. Sci. Sports Exerc. 28: #177 (1996).
81. Bojes, H.K., Mills, E.M. and Kehrer, J.P.: BCL-xL expression and α−tocopherol in human
lung adenocarcinoma A549 cells. The Oxygen Society (1996).
82. Datta, K., Chin, A., Ahmed, T., Qing, W-G., Powell, K.L., Simhambhatla, P., MacLeod, M.C.
and Kehrer, J.P.: Protection against cyclophosphamide-mediated lung and bladder toxicity in mice by 2,6-dithiopurine. Fundam. Appl. Toxicol.36: 213, #1080 (1997).
83. Robertson, J.D., Starnes, J.W. and Kehrer, J.P.: Reducing cosubstrates involved in reducing
cardiac glutathione disulfide. Fundam. Appl. Toxicol.36: 299, #1520 (1997).
84. Horton, N.D., Mamiya, B.M., Bojes, H.K. and Kehrer, J.P.: Relationships between glutathione
levels, cell density and proliferation of A549 cells following treatment with acrolein. Fundam. Appl. Toxicol.36: 126, #642 (1997). Curriculum Vitae Kehrer, J.P. Page 26
85. Datta, K., Xu, J.and Kehrer, J.P.: Changes in bcl-xL and 5-lipoxygenase activator protein
(FLAP) expression following induction of apotposis by a FLAP inhibitor in FL5.12 cells. The Toxicologist 42: 190, #938 (1998).
86. Bojes, H.K., Cohen, G.M. and Kehrer, J.P.: Depletion of intracellular glutathione (GSH)
causes apoptosis in FL5.12 cells. The Toxicologist. 42: 356, #1756 (1998).
87. Horton, N.D., Corrigan, L. and Kehrer, J.P.: The possible role of glutathione (GSH) in
acrolein-decreased NF-κB activation and cell proliferation. The Toxicologist. 42: 278, #1368
88. Robertson, J.D., Datta, K., Xu, J. and Kehrer, J.P.: Bcl-xL overexpression restricts hsp70i
production and heat-induced apoptosis in FL5.12 cells. The Toxicologist. 42: 145, #716 (1998).
89. Robertson, J.D. and Kehrer, J.P.: Proteasome inhibition induces hsp70 and promotes
apoptosis which is abated by bcl-x overexpression in murine pro-B lymphocytic (FL5.12) cell
lines. Presented at 'Mechanisms of Toxicity Gordon Research Conference, Summer 1998
90. Biswal, S., Datta, K. and Kehrer, J.P.: N-Acetyl cysteine (NAC) partially blocks fludarabine-
induced apoptosis in CLL cell lines by acting downstream of caspase-3 activation. The Toxicologist. 48: 155, #727 (1999).
91. Datta, K. and Kehrer, J.P.: MK886, a 5-lipoxygenase activating protein (FLAP) inhibitor,
induces FLAP-independent apoptosis in FL5.12 cells. The Toxicologist. 48: 154, #725 (1999).
92. Robertson, J.D., Datta, K. and Kehrer, J.P.: Proteasome inhibition induces HSP70 and
promotes apoptosis which is decreased by bcl-x overexpression in murine pro-B lymphocytic
(FL5.12) cells. The Toxicologist. 48: 157, #735 (1999).
93. Acquaah-Mensah, G., Biswal, S.S., Kehrer, J.P. and Leslie, S.W.: Redox-sensitive
transcription activity is suppressed at second day post-natal (PD2) in Sprague Dawley rat fetal alcohol syndrome model. Alcoholism, Clin. Exptl. Res. 23: 62A #342 (1999).
94. Biswal, S., Acquaah-Mensah, G., Pabalan, J., Datta, K. and Kehrer, J.P.: Effect of acrolein on
AP-1 and gene expression in A549 cells. The Toxicologist 54: 391, #1836 (2000).
95. Kehrer, J.P., Biswal, S., Thuillier, P., Vanden Heuvel, J.P. and Fischer, S.: Inhibition of
peroxisome proliferator activated receptor alpha by MK886. The Toxicologist 54: 323, #1513 (2000).
96. Datta, K., Biswal, S. and Kehrer, J.P.: Role of proteolysis in bcl-x depletion during MK886-
induced apoptosis in FL5.12 cells. The Toxicologist 54: 358, #1678 (2000).
97. Kern, J.C. and Kehrer, J.P.: Acrolein enhances mechlorethamine-induced apoptosis. TheToxicologist. 54: 113, #534 (2000).
Kehrer, J.P.: The Haber-Weiss reaction and mechanisms of toxicity. The Toxicologist. 54: 129, #611 (2000).
Biswal, S., Thuillier, P., Vanden Heuvel, J.P., Fischer, S. and Kehrer, J.P.: 5-lipoxygenase activating protein inhibitor , MK886, inhibits peroxisome proliferator activated receptor alpha in different cell lines. Proc. Am. Assoc. Cancer Res.91: 374, #2373 (2000). Curriculum Vitae Kehrer, J.P. Page 27
100. Pabalan, J.G., Biswal, S.S., Bowman, P. and Kehrer, J P.: Investigation of anticancer activity
of all-trans-(4-hydroxyphenyl) retinamide in human lung adenocarcinoma A549 cells. Proc. Am. Assoc. Cancer Res.91: 618, #3929 (2000).
101. Dubick, M.A., Pabalan, J.G., Biswal, S., Jordan, B.S., Kehrer, J.P., Goodwin, C.W. and
Bowman, P.D.: Gene expression profiling of the response of human small airway epithelial cells (SAEC) to Douglas Fir smoke. FASEB J.14: 134.4 (2000).
102. Pabalan, J.G., Kehrer, J.P., Goodwin, C.W. and Bowman, P.D.: Gene expression profiling
of the response of human keratinocytes to all trans retinoic acid (ATRA). FASEB J.14: 270.12 (2000).
103. Acquaah-Mensah, G.K., Kehrer, J.P. and Leslie, S.W.: Evidence of ethanol-induced
molecular stress during neurodevelopment. Alcoholism, Clin. Exptl. Res. 24: 31A #146 (2000).
104. Deshpande, V. and Kehrer, J.P.: N-Acetylcysteine enhances apoptosis induced by the 5-
lipoxygenase activating protein (FLAP) inhibitor MK886 in Jurkat cells. The Toxicologist. 60: #1334 (2001).
105. Biswal, S.S., Bowman, P., Datta, K. and Kehrer, J.P.: Smoke- and acrolein-mediated effects
on AP-1 activation and gene expression. The Toxicologist. 60: #1024 (2001).
106. Datta, K., Kern, J.C., Biswal, S.S. and Kehrer, J.P.: Proteolytic depletion of bcl-x and
induction of lysosomal degranulation during MK886-induced apoptosis in FL5.12 cells. The Toxicologist. 60: #1336 (2001).
107. Kern, J.C., Chung, B.C. and Kehrer, J.P.: The importance of caspases in acrolein-induced
oncosis. The Toxicologist. 60: #1337 (2001).
108. Acquaah-Mensah, G.K., Kehrer, J.P. and Leslie, S.W.: Activation of glycogen synthase
kinase-3 in a fetal alcohol syndrome model. Alcoholism, Clin. Exptl. Res. 25: 75A (2001).
109. Kehrer, J.P. and La, E.: Role of fatty acid release and oxidation in apoptosis induced by
lipoxygenase (LOX) inhibitors. Free Rad. Biol. Med.31: 314 Suppl. 1 (2001).
110. Kern, J.C. and Kehrer, J.P.: Acrolein depletes glutathione and thioredoxin in human
bronchiolar cancer cells. The Toxicologist 66: #702, 144 (2002).
111. Kehrer, J.P.: Introduction to thioredoxins and thioredoxin reductases: central roles in toxicity
and cancer. The Toxicologist 66: #270, 56 (2002).
112. La, E, and Kehrer, J.P. Fatty acid release and oxidation as factors in the apoptosis induced by
lipoxygenase inhibitors. The Toxicologist 66: #1102, 225 (2002).
113. Biswal, S.S., Maxwell, T. and Kehrer, J.P.: Modulation of benzo(a)pyrene-induced p53 by
acrolein. The Toxicologist 66: #1504, 307 (2002).
114. Deshpande, V.S. and Kehrer, J.P.: Mechanisms by which N-acetylcysteine enhances
MK886-induced apoptosis. Proc. Am. Assoc. Cancer Res.43: 533, #2645 (2002).
115. Thuillier P., Brash, A.R., Kehrer, J.P., Stimmel, J.B., Leesnitzer, L.M., Yang, P.Y,. Newman,
R.A. and Fischer, S.M.: Inhibitory effects of lipoxygenase inhibitors on PPAR mediated keratinocyte differentiation. Cancer Epidemiol. Biomark. Prevent. 11: C318 Part 2 (2002). Curriculum Vitae Kehrer, J.P. Page 28
116. Atarod, E.B. and Kehrer, J.P.: Oxidant production and apoptosis in response to PPAR
agonists and antagonists. Free Rad. Biol. Med.33: S403 #306 Suppl. 1 (2002).
117. Kern, J.C. and Kehrer, J.P.: The importance of thioredoxin in acrolein-mediated alterations
of NF-κB and AP-1 DNA binding in A549 cells. Free Rad. Biol. Med.33: 353 #146
118. Tong, Z., Wu, Z. and Kehrer, J.P.: Modulation of lipocalin 24p3 expression as an apoptotic
mechanism for MK886. The Toxicologist (2003).
119. Atarod, E.B. and Kehrer, J.P.: Changes in cellular oxidant production in response to
peroxisome proliferators activated receptor (PPAR) α and γ agonists and the PPAR
antagonist MK886. The Toxicologist (2003).
120. Deshpande, V.S. and Kehrer, J.P.: Leucine affects protein translation and apoptosis mediated
by MK886 in Jurkat cells. Proc. Am. Assoc. Cancer Res.44: 1397 #6091 (2003).
121. Tong, Z., Wu, X. and Kehrer, J.P.: The association of apoptosis with the induction of
neutrophil gelatinase associated lipocalin (NGAL). The Toxicologist78: #1629(2004).
122. Choi, Y.E., Yang, X. and Kehrer, J.P.: Thioredoxin and the toxicity of acrolein. TheToxicologist 78: #972 (2004).
123. Deshpande, V.S. and Kehrer, J.P.: Mechanisms of nordihydroguaiaretic acid (NDGA)-
mediated apoptosis in FL5.12 cells. The Toxicologist 78: #1633(2004).
124. Tong, Z., Wu, X. and Kehrer, J.P.: Akt plays a role in the apoptosis induced by the 5-
lipoxygenase activating protein (FLAP) inhibitor, MK886. The Toxicologist 78: #1630 (2004).
125. Tipple, T.E., Choi, Y.E., Rogers, L.K., Hansen, T.N., Welty, S.E., Kehrer, J.P., and Smith,
C.V.: Enhanced expression of thioredoxin-2 in mice genetically deficient in glutathionereductase. Pediatr Res. 2004.
126. Choi, Y.E. and Kehrer, J.P.: IAP expression is deceased in cells undergoing apoptosis after
treatment with phosphoinositide-dependent kinase 1 (PDK1) inhibitors. Exp. Biol. (2005)
127. Kehrer, J.P., Wu, X., Zhu, J., Chen, C-S., and Tong, Z.: Induction of apoptosis by
phosphoinositide-dependent kinase 1 (PDK1) inhibitors in human non-small cell lungcancer A549 cells is through the mitochondrial pathway. Exp. Biol. (2005)
128. Mitra, S. and Kehrer, J.P.: Mechanisms of diethylmaleate (DEM)-mediated apoptosis in
human T lymphocyte Jurkat cells. Exp. Biol. (2005)
129. Tong, Z., Wu, X., Ovcharenko, D. and Kehrer, J.P.: Neutrophil gelatinase associated
lipocalin (NGAL) and 24p3 as survival factors. Exp. Biol. (2005)
130. Deshpande, V.S. and Kehrer, J.P.: Nordihydroguairetic acid (NDGA)-induced apoptosis
involves activation of the extracellular signal-regulated kinase (ERK) and c-jun-NH2
terminal kinase (JNK) pathways. Exp. Biol. (2005)
Curriculum Vitae Kehrer, J.P. Page 29 Book Reviews
1. The Role of Chemical Mediators in the Pathophysiology of Acute Illness and Injury. R.
McConn (ed.). Raven Press, NY, 1982. Amer. J. Pharmac. Ed. 47: 195 (1983). Cancer of the Respiratory Tract: Predisposing Factors. (Carcinogenesis - A Comprehensive Survey, Vol. 8) M.J. Mass, D.G. Kaufman, J.M. Siegfried, V.E. Steele and S. Nesnow (eds.) Raven Press, NY, 1985. J. Toxicol. Environ. Health 16: 661-662 (1985). New Concepts and Developments in Toxicology. (Proceedings of the Fourth International Congress of Toxicology held in Tokyo, Japan, July 21-25, 1986.) P.L. Chambers, P. Gehring and F. Sakai, (eds.) Elsevier, Amsterdam, 1986. J. Toxicol. Environ. Health 22: 363-364 (1987). A Textbook of Modern Toxicology. E. Hodgson and P.E. Levi, Elsevier, NY, 1987. J. Toxicol. Environ. Health 23: 140-141 (1988). Lipid Peroxidation in Biomembranes. V.E. Kagan, CRC, Boca Raton, FL, 1988. Free Rad. Biol. Med. 6: 447 (1989). Combination Effects in Chemical Carcinogenesis. D. Schmähl, VCH, Weinheim, FRG, 1988. J. Toxicol. Environ. Health 26: 510-511 (1989). Concepts in Inhalation Toxicology. R. McClellan and R. Henderson (eds.) Hemisphere, London, 1989. Toxicol. Lett. 48: 213-214 (1989). Introduction to Toxicology. by J.A. Timbrell, Taylor & Francis, London, 1989. Toxicol. Lett. 51: 233-234 (1990). Basic Toxicology: Fundamentals, Target Organs, and Risk Assessment. by Frank C. Lu, Hemisphere, Philadelphia, 1991. Toxicol. Lett. 55: 351-352 (1991).
10. Hazardous Materials Toxicology: Clinical Priciples of Environmental Health. J.B. Sullivan
and G.R. Krieger (eds.), Williams & Wilkins, 1992. Toxicol. Lett. 61: 319-320 (1992).
11. Toxicology of the Lung. D.E. Gardner, J.D. Crapo, and R.O. McClellan (eds.), Raven, 1992.
Toxicol. Lett. 70: 123-124 (1994). Professional Publications
1. "Consumer Drug File": A drug information column for the general public. Syndicated by: International Medical Tribune Syndicate Written by: Dr. James P. Kehrer and Daniel M. Kehrer from March 1982 - Feb. 19852.
Kehrer, J.P. and Kehrer, D.M.: The real dope on diet drugs. New Body 1, 22 (1982).
Kehrer, J.P. and Kehrer, D.M.: Consumers benefit from advertising prescription drugs. Newsday, July 23, 1982. p. 68.
Kehrer, J.P. and Kehrer, D.M.: Pills have a success story to be told.but are they necessary incapsule form? The Philadelphia Inquirer, Oct. 13, 1982, p. 15A.
Kehrer, D.M. and Kehrer, J.P.: Pain Relievers and Packaging. St. Louis Post-Dispatch,October 24, 1982.
Kehrer, J.P. and Kehrer, D.M.: Tylenol Tampering Scare Raises Questions. AustinAmerican-Statesman, November 11, 1982, A24.
Kehrer, J.P. and Kehrer, D.M.: Going Underground for Birth Control. Des Moines Register,March 14, 1983, 7A.
Kehrer, D.M. and Kehrer, J.P.: Revolution Over the Counter. Amer. Health 2, 96 (1983).
Kehrer, J.P. and Kehrer, D.M.: Birth-control drug no-win proposition. Austin American-Statesman, May 25, 1983, A11.
10. Kehrer, J.P. and Kehrer, D.M.: New ways to take drugs. Fact 2, 23 (1983). 11. Kehrer, J.P. and Kehrer, D.M.: New consumer drug discoveries. Fact 2, 72 (1983). 12. Kehrer, D.M. and Kehrer, J.P.: When advice is poison. Amer. Health 3, 79 (1984). 13. Kehrer, D.M. and Kehrer, J.P.: What you must know about prescription drugs. Parade
14. Kehrer, D.M. and Kehrer, J.P.: Good-bye to pills and needles. Washington Post, April 9,
Curriculum Vitae Kehrer, J.P. Page 30
15. Combs, A.B. and Kehrer, J.P.: How to convert a database from DB Master™ to MS File™.
Random Access 5 (4): 1 (1987).
16. Kehrer, J.P.: Introduction to Internet mail. Society of Toxicology Communiqué. January/
16. Kehrer, J.P.: A brief introduction to internet mail. Eurotox Newsletter 18: 36-38 (1995).
"Pills and Potions: New Discoveries About Prescription and Over-the-Counter Drugs" by: James P.
Kehrer, Ph.D. and Daniel M. Kehrer. Publisher: Arco Press, New York, NY, April, 1984
This book was designed to acquaint the general public with recently approved drugs, other drugs which may beapproved in the near future, and coming changes in how drugs are delivered as part of our health care system.
Hypospadias in Males With Intrauterine GrowthRestriction Due To Placental Insufficiency:The Placental Role in the Embryogenesis ofMale External GenitaliaYoav Yinon,1 John C.P. Kingdom,1 Leslie K. Proctor,1 Edmond N. Kelly,2 Joao L. Pippi Salle,3Diane Wherrett,4 Sarah Keating,5 Ori Nevo,6 and David Chitayat7*1Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The Placenta
What Happened To My Gut? (A Story About What CAN Happen To Your Bunny If You Don’t Feed It Right) By Sharon Hollars, DVM Nutrition is one of the main keys to keeping rabbits healthy. The first article, “I Know Bunnies Like Carrots, But What Should My Bunny REALLY Eat?” discusses what you SHOULD be feeding your bunny. This article covers some of the more common things that ca